Showing results (71-80 of 93) with videos related to
Sort By:
Pageof 10
Journal of Medical Economics|July 13, 2023
Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 studyYen Chung, Diego J Maselli, Fan Mu, et al.Journal of Managed Care & Specialty Pharmacy|June 16, 2022
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapyMichelle Choi, Jinlin Song, Cat N Bui, et al.Journal of Managed Care Pharmacy : JMCP|December 5, 2012
Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychoticsVanja Sikirica, Steven R Pliszka, Keith A Betts, et al.Journal of Alzheimer'S Disease : JAD|November 29, 2024
Real-world diagnostic, referral, and treatment patterns in early Alzheimer's disease among community-based practices in the United StatesTimothy R Juday, Ashley Holub, Soeren Mattke, et al.Advances in Therapy|December 27, 2021
Real-World Management of Hyperkalemia in the Emergency Department: An Electronic Medical Record AnalysisJill Davis, Rubeen Israni, Keith A Betts, et al.Oncology and Therapy|August 10, 2024
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell CarcinomaElla Xiaoyan Du, Keith A Betts, Travis Wang, et al.Advances in Therapy|January 3, 2024
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsEduardo Mysler, Gerd R Burmester, Christopher D Saffore, et al.International Journal of Radiation Oncology, Biology, Physics|June 10, 2008
Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matterMohamed A Alm El-Din, Kevin S Hughes, Dianne M Finkelstein, et al.Cancer Immunology, Immunotherapy : CII|October 5, 2022
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survivalJeffrey S Weber, Tayla Poretta, Brian D Stwalley, et al.The American Journal of Managed Care|November 4, 2014
Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorderVanja Sikirica, Steven R Pliszka, Keith A Betts, et al.Pageof 10